Evolocumab

Thousand Oaks, Calif. – August 31, 2026 Amgen announced new Phase 3 findings showing that Repatha® (evolocumab) reduced the...

SOUTH SAN FRANCISCO, Calif., July 30, 2026 Cytokinetics, Incorporated has achieved a major regulatory and market access milestone for...

THOUSAND OAKS, Calif., July 29, 2026 Amgen has announced that the Committee for Medicinal Products for Human Use (CHMP)...